Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) has earned a consensus ra

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clini

Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) hit a new 52-week low dur

NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of nea

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) have received a

LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen

Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug,

Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule

Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candid

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classif

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clin

Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a glo

Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GL

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising compet

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 por

Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market O

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk an

Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in develo

Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.35) per share which met the an

Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company develo

Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment,

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with

https://www.barrons.com/articles/structure-therapeutics-weight-loss-pill-trial-stock-93dba470

Structure Therapeutics' Phase 2 ACCESS II trial shows up to 16.3% placebo-adjusted weight loss f

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market O

Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.36) per share which beat the a

https://www.axios.com/pro/biotech-deals/2026/01/30/structure-therapeutics-pharmas-next-buyout-glp1

Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combinati

JP Morgan analyst Hardik Parikh maintains Structure Therapeutics (NASDAQ:GPCR) with a Overweight

Guggenheim analyst Seamus Fernandez maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the compan

https://www.bloomberg.com/news/videos/2026-01-14/structure-therapeutics-ceo-stevens-on-pipeline-stra

The Benzinga Stock Whisper Index highlights five stocks seeing strong interest from readers and a lo